| Michael David Ross, MD, PHD | |
|
1914 Lelaray St, Colorado Springs, CO 80909-2800 | |
| (719) 632-7641 | |
| (719) 632-2925 |
| Full Name | Michael David Ross |
|---|---|
| Gender | Male |
| Speciality | Nephrology |
| Experience | 20 Years |
| Location | 1914 Lelaray St, Colorado Springs, Colorado |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679605265 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 50817 (Colorado) | Primary |
| 207R00000X | Internal Medicine | 50817 (Colorado) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uch-memorial Health System | Colorado springs, CO | Hospital |
| San Luis Valley Health | Alamosa, CO | Hospital |
| Spanish Peaks Regional Health Center | Walsenburg, CO | Hospital |
| Uchealth Pikes Peak Regional Hospital | Woodland park, CO | Hospital |
| Prowers Medical Center | Lamar, CO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pikes Peak Nephrology Associates Pc | 7719884931 | 11 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
A new study on the relationship between nonalcoholic fatty liver disease (NAFLD) and heart disease found that patients with an elevated level of the enzyme associated with NAFLD had an increased risk of coronary heart disease, which appears to be related to insulin resistance, obesity and central fat distribution.
The vast majority of reviews on psychotropic drugs is focused on the potential benefits that may have. However, the vulnerabilities induced by treatment need also to be considered.
A study released this week suggests that anti-cancer chemotherapies which use nanoparticles to deliver drugs deep inside tumor tissue will be more effective if the particles are positively electrically charged because they are taken up to a greater extent by proliferating cells, according to a team of chemists and chemical engineers at the University of Massachusetts Amherst.
Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ systems, a durable and effective catheter based in-office alternative to drugs or surgery for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fourth quarter ended June 30, 2009 and for fiscal year 2009.
› Verified 4 days ago
| Entity Name | Pikes Peak Nephrology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1407833767 PECOS PAC ID: 7719884931 Enrollment ID: O20031216000741 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
A new study on the relationship between nonalcoholic fatty liver disease (NAFLD) and heart disease found that patients with an elevated level of the enzyme associated with NAFLD had an increased risk of coronary heart disease, which appears to be related to insulin resistance, obesity and central fat distribution.
The vast majority of reviews on psychotropic drugs is focused on the potential benefits that may have. However, the vulnerabilities induced by treatment need also to be considered.
A study released this week suggests that anti-cancer chemotherapies which use nanoparticles to deliver drugs deep inside tumor tissue will be more effective if the particles are positively electrically charged because they are taken up to a greater extent by proliferating cells, according to a team of chemists and chemical engineers at the University of Massachusetts Amherst.
Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ systems, a durable and effective catheter based in-office alternative to drugs or surgery for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fourth quarter ended June 30, 2009 and for fiscal year 2009.
› Verified 4 days ago
| Entity Name | Salida Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972778272 PECOS PAC ID: 3577451152 Enrollment ID: O20040413000292 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
A new study on the relationship between nonalcoholic fatty liver disease (NAFLD) and heart disease found that patients with an elevated level of the enzyme associated with NAFLD had an increased risk of coronary heart disease, which appears to be related to insulin resistance, obesity and central fat distribution.
The vast majority of reviews on psychotropic drugs is focused on the potential benefits that may have. However, the vulnerabilities induced by treatment need also to be considered.
A study released this week suggests that anti-cancer chemotherapies which use nanoparticles to deliver drugs deep inside tumor tissue will be more effective if the particles are positively electrically charged because they are taken up to a greater extent by proliferating cells, according to a team of chemists and chemical engineers at the University of Massachusetts Amherst.
Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ systems, a durable and effective catheter based in-office alternative to drugs or surgery for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fourth quarter ended June 30, 2009 and for fiscal year 2009.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael David Ross, MD, PHD 1914 Lelaray St, Colorado Springs, CO 80909-2800 Ph: (719) 632-7641 | Michael David Ross, MD, PHD 1914 Lelaray St, Colorado Springs, CO 80909-2800 Ph: (719) 632-7641 |
News Archive
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.
A new study on the relationship between nonalcoholic fatty liver disease (NAFLD) and heart disease found that patients with an elevated level of the enzyme associated with NAFLD had an increased risk of coronary heart disease, which appears to be related to insulin resistance, obesity and central fat distribution.
The vast majority of reviews on psychotropic drugs is focused on the potential benefits that may have. However, the vulnerabilities induced by treatment need also to be considered.
A study released this week suggests that anti-cancer chemotherapies which use nanoparticles to deliver drugs deep inside tumor tissue will be more effective if the particles are positively electrically charged because they are taken up to a greater extent by proliferating cells, according to a team of chemists and chemical engineers at the University of Massachusetts Amherst.
Urologix®, Inc. (NASDAQ:ULGX), a medical device company focused on developing, manufacturing and marketing Cooled ThermoTherapy™ systems, a durable and effective catheter based in-office alternative to drugs or surgery for patients suffering from benign prostatic hyperplasia (BPH), today reported financial results for the fourth quarter ended June 30, 2009 and for fiscal year 2009.
› Verified 4 days ago
Michael Judd Burkholz, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 2940 N Circle Dr, Colorado Springs, CO 80909 Phone: 719-635-7321 Fax: 719-635-2510 | |
Mrs. Rachel Elizabeth Black, DO Nephrology Medicare: Medicare Enrolled Practice Location: 2222 N Nevada Ave Ste 4004, Colorado Springs, CO 80907 Phone: 719-471-7064 | |
William A Munson, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 325 E Fontanero St, Colorado Springs Endocrine Clinic Pc, Colorado Springs, CO 80907 Phone: 719-636-3829 Fax: 719-636-1387 | |
Barbara E Johnston, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 175 S Union Blvd Ste 350, Colorado Springs, CO 80910 Phone: 719-633-5515 Fax: 719-365-1307 | |
Dr. Raymond L. Wahl, M.D. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 2502 E Pikes Peak Ave, Colorado Springs, CO 80909 Phone: 719-630-6440 Fax: 719-228-6603 | |
Dr. Duane Ryan Spaulding, M.D., F.A.C.P. Nephrology Medicare: Not Enrolled in Medicare Practice Location: 6722 Northface Ln, Colorado Springs, CO 80919 Phone: 719-590-9338 | |
Dr. Wendy Marie Bamberg, MD Nephrology Medicare: Not Enrolled in Medicare Practice Location: 301 S Union Blvd, Colorado Springs, CO 80910 Phone: 719-578-3199 |